Harmony Outcomes: a randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes …
Background Albiglutide is a long-acting glucagon-like peptide-1 receptor agonist that improves
glycemic control in patients with type 2 diabetes mellitus (T2DM). Harmony Outcomes is …
glycemic control in patients with type 2 diabetes mellitus (T2DM). Harmony Outcomes is …
Time course of degradation of cardiac troponin I in patients with acute ST-elevation myocardial infarction: the ASSENT-2 troponin substudy
…, T Lund, VL Serebruany, CB Granger… - Circulation …, 2006 - Am Heart Assoc
Although measurement of troponin is widely used for diagnosing acute myocardial infarction
(AMI), its diagnostic potential may be increased by a more complete characterization of its …
(AMI), its diagnostic potential may be increased by a more complete characterization of its …
Genetic effects in the leukotriene biosynthesis pathway and association with atherosclerosis
…, JM Vance, J Rose, CB Granger… - Human genetics, 2009 - Springer
Leukotrienes are arachidonic acid derivatives long known for their inflammatory properties
and their involvement with a number of human diseases, most particularly asthma. Recently, …
and their involvement with a number of human diseases, most particularly asthma. Recently, …
Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of …
…, S Goodman, K Houbracken, K Munsters, CB Granger… - Circulation, 2001 - Am Heart Assoc
Background—Early reinfarction after thrombolytic therapy is associated with adverse outcomes
and increased mortality. Among patients with reinfarction in the 1992 Global Utilization of …
and increased mortality. Among patients with reinfarction in the 1992 Global Utilization of …
ST resolution 1 hour after fibrinolysis for prediction of myocardial infarct size: insights from ASSENT 3
Acute ST-segment elevation myocardial infarction requires prompt restoration of myocardial
perfusion to salvage myocardium at risk of ischemic necrosis and improve clinical outcome. …
perfusion to salvage myocardium at risk of ischemic necrosis and improve clinical outcome. …
Pharmacogenomic study of heart failure and candesartan response from the CHARM programme
Aims The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM)
programme consisted of three parallel, randomized, double‐blind clinical trials …
programme consisted of three parallel, randomized, double‐blind clinical trials …
Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): rationale and design
Background: Chronic heart failure (CHF) is an increasing burden to health care. Pharmacological
treatment with angiotensin-converting enzyme (ACE) inhibitors and beta blockers …
treatment with angiotensin-converting enzyme (ACE) inhibitors and beta blockers …
Out-of-hospital cardiac arrest resuscitation systems of care: a scientific statement from the American Heart Association
…, JL Garvey, JP Ornato, L Gonzales, CB Granger… - Circulation, 2018 - Am Heart Assoc
The American Heart Association previously recommended implementation of cardiac
resuscitation systems of care that consist of interconnected community, emergency medical …
resuscitation systems of care that consist of interconnected community, emergency medical …
Effect of candesartan on New York Heart Association functional class: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity …
…, E Michelson, C Granger, B Olofsson… - European heart …, 2004 - academic.oup.com
Aims To evaluate the effect of the angiotensin receptor blocker candesartan on New York
Heart Association (NYHA) functional class in a broad spectrum of patients with chronic heart …
Heart Association (NYHA) functional class in a broad spectrum of patients with chronic heart …
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo …
…, B Thomas, J Rich, S Bartone, G Beaulieu, K Brown… - The Lancet, 2018 - thelancet.com
Background Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration
of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly …
of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly …